Cerebrolysin Dosage Guide

Evidence-based protocols for the most clinically studied neuropeptide preparation — neurotrophic factor activity, IM and IV administration, intensive cycling, stacking with Semax and Selank, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

Cerebrolysin

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is Cerebrolysin?

Cerebrolysin is a porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids, obtained through standardized enzymatic breakdown of purified porcine brain proteins. Manufactured by EVER Neuro Pharma (Austria), it is one of the most extensively studied neuropeptide preparations in clinical medicine — approved as a prescription drug in over 40 countries for stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia.

Unlike synthetic single-peptide compounds, Cerebrolysin is a multi-component biological preparation. Its peptide fraction (approximately 25% of the total content) contains fragments with neurotrophic factor-like activity that mimic the actions of endogenous brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and nerve growth factor (NGF). The remaining approximately 75% consists of free amino acids that serve as substrates for neuronal metabolism.

Cerebrolysin's mechanism of action is multi-modal: it promotes neuroplasticity, reduces neuroinflammation, inhibits calpain-mediated neurodegeneration, enhances synaptic repair, and supports neurogenesis. These effects have been demonstrated in extensive preclinical research and confirmed in large-scale clinical trials including the CASTA trial (stroke) and CERE-LYSE trial (TBI).

A critical distinction from most research peptides: Cerebrolysin is administered by intramuscular (IM) or intravenous (IV) injection only — never subcutaneously. It comes as a ready-to-use amber solution (215.2 mg/mL concentrate) in glass ampules, requiring no reconstitution.

Use our Peptide Dosage to help plan your dosing protocol and volume calculations.

Dosing information in this guide is derived from clinical trial protocols, approved prescribing information from countries where it is registered, and clinical practice guidelines and community protocols.

Key Characteristics:

Porcine brain-derived neuropeptide preparation — standardized mixture of low-molecular-weight neuropeptides (~25%) and free amino acids (~75%) from enzymatic breakdown of purified porcine brain proteins
Multi-modal neurotrophic activity — mimics endogenous BDNF, GDNF, CNTF, and NGF-like signaling; promotes neuroplasticity, reduces neuroinflammation, inhibits calpain-mediated neurodegeneration
IM or IV injection only — NOT subcutaneous — this is the most critical administration distinction from most research peptides
Ready-to-use solution — 215.2 mg/mL Cerebrolysin concentrate in glass ampules; no reconstitution needed; clear amber-yellow liquid
Short intensive cycling — administered in 10–21 day cycles repeated every 3–6 months — not continuous daily use
Extensive clinical evidence — approved as prescription drug in 40+ countries; Phase III/IV trials in stroke (CASTA), TBI (CERE-LYSE), and dementia; over 40 years of clinical use

For a complete overview of its mechanism and research, see our full Cerebrolysin profile. New to peptides? Start with the Beginner's Guide to Peptides.

How Cerebrolysin Dosage Is Determined

Cerebrolysin dosing is uniquely well-supported by clinical evidence compared to most neuropeptide compounds. Dosing protocols are derived from large-scale randomized controlled trials, decades of post-marketing surveillance in countries where it is approved, and established clinical practice guidelines. The evidence base includes thousands of patients across multiple indications.

Stroke Clinical Trials

The CASTA (Cerebrolysin in Acute STroke in Asia) trial, one of the largest Cerebrolysin studies, evaluated 30 mL IV daily for 10 days in acute ischemic stroke patients. The trial enrolled over 1,000 patients across multiple centers. While the primary endpoint results were debated, subgroup analyses and meta-analyses of multiple stroke trials have demonstrated neurological improvement at doses of 20–50 mL IV daily when initiated within 24–72 hours of stroke onset.

Traumatic Brain Injury Trials

The CERE-LYSE trial and subsequent TBI studies used 30–50 mL IV daily for 10–21 days in moderate-to-severe TBI patients. Results demonstrated improved neurological outcomes and cognitive recovery compared to placebo. These trials established the high-dose IV protocol used in acute neurological injury settings.

Dementia and Cognitive Studies

Multiple randomized controlled trials in Alzheimer's disease and vascular dementia have used 10–30 mL IV daily for 20–28 day cycles, repeated at intervals of 2–3 months. Alvarez et al. demonstrated sustained cognitive improvement on ADAS-cog scores with repeated 4-week cycles of 10 mL IV Cerebrolysin in Alzheimer's patients, with benefits persisting between treatment cycles.

Dose-Response Relationship

Clinical evidence supports a clear dose-response relationship. Lower doses (5 mL IM) produce measurable neurotrophic effects suitable for mild cognitive support. Moderate doses (10–20 mL) are used for dementia and chronic neurological conditions. High doses (30–50 mL IV) are reserved for acute conditions (stroke, TBI) under clinical supervision. The concentration of the preparation is standardized, so dosing is expressed in milliliters of solution rather than milligrams of peptide content.

Strength of evidence: Strong. Cerebrolysin has one of the strongest clinical evidence bases of any neuropeptide preparation, including multiple Phase III and Phase IV randomized controlled trials, systematic reviews, and meta-analyses across stroke, TBI, and dementia indications. Dosing protocols are derived from pharmaceutical-grade clinical research, not community anecdote. The evidence is substantially stronger for neurological disease states than for cognitive enhancement in healthy individuals.

Standard Cerebrolysin Dosage Ranges

Cerebrolysin is administered by intramuscular (IM) or intravenous (IV) injection. Doses are expressed in milliliters of the standardized 215.2 mg/mL solution. The appropriate dose, route, and cycle length depend on the indication and severity of the condition being addressed.

Dosage by Indication

Indication	Daily Dose	Route	Cycle Length	Notes
Cognitive Enhancement / Nootropic	5 mL	IM	10–20 days	Conservative approach for healthy individuals; repeat every 3–6 months
Moderate Neurological Conditions	10 mL	IM or IV	10–20 days	Chronic cognitive impairment, mild-to-moderate dementia; repeat every 3–6 months
Alzheimer's / Vascular Dementia	10–30 mL	IV	20–28 days	Clinical trial protocols; repeated cycles every 2–3 months; medical supervision required
Acute Ischemic Stroke	20–50 mL	IV infusion	10–21 days	Initiated within 24–72 hours of onset; clinical setting only; diluted in saline
Traumatic Brain Injury	30–50 mL	IV infusion	10–21 days	Moderate-to-severe TBI; clinical setting only; diluted in 100–250 mL saline
Pediatric Brain Injury	0.1–0.2 mL/kg	IM or IV	10–20 days	Specialist supervision required; dose calculated by body weight

Volume and Route Guidelines

Up to 5 mL: Can be given as a single IM injection (gluteal or deltoid muscle)
5–10 mL: Can be given IM (split across two injection sites if needed) or as a slow IV push
Above 10 mL: Must be administered as IV infusion, diluted in 100–250 mL of physiological saline, infused over 15–60 minutes
Above 50 mL: Not recommended; no additional benefit demonstrated in clinical trials

IM or IV only — NEVER subcutaneous. This is the single most important administration rule for Cerebrolysin. Unlike BPC-157, Semax, or most other research peptides, Cerebrolysin cannot be injected subcutaneously. For doses above 10 mL, IV administration with saline dilution is mandatory. IV doses should be administered under clinical supervision.

Administration Routes: IM vs. IV

The choice between intramuscular and intravenous administration depends on the dose, the indication, and the clinical setting. Both routes are effective, but they differ in practicality, onset, and suitability for different dose ranges.

Parameter	Intramuscular (IM)	Intravenous (IV)
Maximum Volume	5 mL per injection site	Up to 50 mL (diluted in saline)
Typical Dose Range	1–10 mL daily	10–50 mL daily
Best For	Nootropic use, mild-to-moderate conditions	Acute stroke, TBI, severe dementia
Setting	Can be self-administered at home	Clinical supervision recommended
Onset	Gradual absorption from muscle tissue	Rapid systemic distribution
Injection Site	Gluteal or deltoid muscle	Antecubital vein (slow push or infusion)
Dilution Required?	No	Yes (above 10 mL — dilute in 100–250 mL saline)
Pain / Discomfort	Injection site soreness is common	Minimal if infused slowly; phlebitis risk if technique is poor

IM Injection Technique for Cerebrolysin

Needle gauge: 21–23 gauge, 1–1.5 inch needle (must reach muscle tissue — insulin syringes are NOT suitable for IM injection)
Injection sites: Gluteal (upper outer quadrant of buttock) or deltoid muscle. Rotate sites between injections.
Volume limit: Maximum 5 mL per injection site. If your daily dose exceeds 5 mL, split across two sites (e.g., left and right gluteal).
Technique: Insert needle at 90-degree angle to skin surface. Aspirate briefly to confirm you are not in a blood vessel. Inject slowly over 1–2 minutes for volumes above 2 mL to reduce discomfort.
Post-injection: Gentle massage of the injection site may help reduce soreness and improve absorption.

For most nootropic and cognitive enhancement users: The 5 mL IM daily protocol is the practical choice. It does not require IV equipment, clinical supervision, or saline dilution. It is the most common protocol used outside of hospital settings and is well-supported by clinical evidence for mild-to-moderate indications.

Calculate Your Cerebrolysin Dose

Unlike lyophilized peptides that require reconstitution, Cerebrolysin is supplied as a ready-to-use solution in pre-filled glass ampules. No reconstitution math is needed. The concentration is standardized at 215.2 mg/mL of Cerebrolysin concentrate. Your dose is simply the volume you draw from the ampule.

Available Ampule Sizes:

1 mL ampule — 215.2 mg Cerebrolysin concentrate
2 mL ampule — 430.4 mg Cerebrolysin concentrate
5 mL ampule — 1,076 mg Cerebrolysin concentrate
10 mL ampule — 2,152 mg Cerebrolysin concentrate
20 mL vial — 4,304 mg Cerebrolysin concentrate (for IV use)
30 mL vial — 6,456 mg Cerebrolysin concentrate (for IV use)

Quick Reference — Daily Dose Planning

Daily Dose	Ampule Selection	Route	10-Day Cycle Supply
5 mL	1 × 5 mL ampule	IM (single injection)	10 ampules (5 mL)
10 mL	2 × 5 mL or 1 × 10 mL	IM (2 sites) or IV push	10 ampules (10 mL) or 20 ampules (5 mL)
20 mL	1 × 20 mL vial	IV infusion (dilute in saline)	10 vials (20 mL)
30 mL	1 × 30 mL vial	IV infusion (dilute in saline)	10 vials (30 mL)

Single-use ampules: Each Cerebrolysin ampule is intended for single use. Once opened, the solution must be used immediately — it contains no preservatives. Do not store opened ampules for later use. If your daily dose is less than the ampule volume, the remainder must be discarded. Plan your ampule selection to minimize waste.

Plan Your Protocol — Use Our

Calculate your total Cerebrolysin supply needs based on daily dose and cycle length — instant volume and ampule calculations.

Cerebrolysin Dosage by Goal

Cerebrolysin's multi-modal neurotrophic mechanism makes it applicable to a range of neurological goals — from mild cognitive enhancement to acute neuroprotection. The optimal protocol varies significantly by indication. Choose the protocol that matches your situation and adjust based on clinical guidance.

Cognitive Enhancement & Nootropic Use

For healthy individuals or those with mild age-related cognitive decline seeking improved mental clarity, focus, memory consolidation, and verbal fluency. This is the most conservative protocol and the most common for non-clinical use. Evidence is primarily from smaller studies and clinical extrapolation from dementia trials.

Dose: 5 mL IM once daily
Cycle: 10–20 days
Repeat: Every 3–6 months
Expected onset: Subjective improvements typically reported within 3–7 days; peak effects at end of cycle
Note: Benefits may persist 2–4 months after cycle completion due to sustained neurotrophic cascades

Neuroprotection & Neuroregeneration

For individuals recovering from mild TBI, concussion, or seeking neuroprotection following neurological insults. Moderate dosing provides meaningful neurotrophic support without requiring IV administration. Should be initiated as early as possible after the insult.

Dose: 10 mL IM daily (split across two 5 mL injection sites) or 10 mL IV push
Cycle: 10–21 days
Repeat: Second cycle after 4–8 week break if needed
Note: Earlier initiation after neurological insult is associated with better outcomes in clinical data

Alzheimer's Disease & Dementia Support

Based on clinical trial protocols for mild-to-moderate Alzheimer's disease and vascular dementia. Requires IV administration and medical supervision. Multiple repeated cycles have demonstrated cumulative cognitive benefit in controlled studies.

Dose: 10–30 mL IV infusion daily (diluted in 100–250 mL saline)
Cycle: 20–28 days
Repeat: Every 2–3 months for sustained benefit
Setting: Clinical supervision required for IV administration
Evidence: ADAS-cog improvement demonstrated in RCTs; benefits sustained between treatment cycles with repeated administration

Clinical evidence supports repeated cycling. Studies by Alvarez et al. and others have shown that Cerebrolysin's cognitive benefits in dementia patients are cumulative with repeated cycles. A single cycle produces improvement, but repeated cycles every 2–3 months produce sustained and potentially progressive benefit. This supports the cyclic dosing paradigm over continuous administration.

Acute Ischemic Stroke

Based on the CASTA trial and other stroke studies. High-dose IV Cerebrolysin initiated within the acute window following ischemic stroke. This is exclusively a clinical / hospital protocol and is not suitable for self-administration.

Dose: 30–50 mL IV infusion daily (diluted in 100–250 mL saline, infused over 20–60 minutes)
Cycle: 10–21 days, beginning within 24–72 hours of stroke onset
Setting: Hospital / clinical setting only; not a self-administration protocol

Traumatic Brain Injury (TBI)

Based on the CERE-LYSE trial and related TBI research. High-dose IV protocol for moderate-to-severe TBI, initiated as early as possible after injury. Exclusively a clinical protocol.

Dose: 30–50 mL IV infusion daily
Cycle: 10–21 days, initiated within 24 hours of injury when possible
Setting: Hospital / clinical setting only
Follow-up: Subsequent 10 mL cycles may be considered during rehabilitation phase

Acute stroke and TBI protocols are clinical procedures. The high-dose IV protocols described above are performed in hospital settings under medical supervision. They require IV infusion equipment, saline dilution, vital sign monitoring, and access to emergency medical care. These are NOT self-administration protocols.

Cycling Protocols

Cerebrolysin is fundamentally a cyclic treatment. Unlike peptides such as BPC-157 or Semax that are sometimes used continuously, Cerebrolysin is always administered in short intensive bursts followed by extended rest periods. This is not a community preference — it is the standard clinical protocol established through decades of use in dozens of countries.

Why cycling works for Cerebrolysin: The neurotrophic effects of Cerebrolysin initiate downstream signaling cascades (BDNF, GDNF, CNTF, NGF-like pathways) that persist well beyond the active treatment period. A 10–21 day cycle activates these cascades, and the biological effects continue for weeks to months after the last injection. Continuous daily administration is unnecessary and has not been studied for safety beyond standard cycle lengths.

Standard Cycling Protocols

Protocol	Active Cycle	Rest Period	Best For
Short Nootropic Cycle	10 days daily	3–6 months	Cognitive enhancement in healthy individuals; minimal commitment
Standard Clinical Cycle	20 days daily	2–3 months	Chronic cognitive conditions, post-injury recovery; based on dementia trial protocols
Extended Clinical Cycle	21–28 days daily	2–3 months	Alzheimer's / vascular dementia; based on Alvarez et al. protocols
Acute Neurological Cycle	10–21 days daily	As clinically indicated	Acute stroke, TBI; clinical setting only; may be followed by rehabilitation-phase cycles
Repeated Cycling (Long-term)	20 days every 3 months	~2.5 months between cycles	Year-round neurotrophic support; 3–4 cycles per year

Year-Round Neurotrophic Strategy

For users seeking sustained neurotrophic support throughout the year, a repeated cycling approach provides the most consistent benefit. Run 3–4 Cerebrolysin cycles per year (e.g., one cycle every 3 months), with each cycle lasting 10–20 days. Between Cerebrolysin cycles, complementary nootropic peptides such as Semax (intranasal) or Selank (intranasal) can provide continuous neurotrophic support through different mechanisms.

Signs Your Cycle Is Working

Improved mental clarity and focus, particularly during demanding cognitive tasks
Enhanced verbal fluency and word recall
Better memory consolidation and faster learning of new information
Improved mood stability and reduced brain fog
Greater resilience to mental fatigue during prolonged cognitive work
In neurological conditions: measurable improvement on cognitive assessments

Peak effects often appear after the cycle ends. Many users report maximum cognitive benefit 1–4 weeks after completing a Cerebrolysin cycle, as downstream neurotrophic cascades reach full activation. Do not judge the cycle solely by how you feel during active treatment — the sustained post-cycle benefit window is a hallmark of Cerebrolysin's mechanism.

Cerebrolysin Stacking Protocols

Cerebrolysin can be stacked with complementary nootropic and neuroprotective peptides that act through different mechanisms. The goal of stacking is to engage multiple neurotrophic and neuroprotective pathways simultaneously for broader and more robust cognitive support. Cerebrolysin provides the neurotrophic foundation via IM/IV injection, while complementary peptides add specific mechanisms.

Cerebrolysin + Semax — Comprehensive Neurotrophic Stack

The most popular Cerebrolysin stack. Semax is a synthetic heptapeptide analogue of ACTH(4–10) that upregulates BDNF expression through a mechanism complementary to Cerebrolysin's multi-component neurotrophic activity. Semax is administered intranasally, making it convenient to combine with Cerebrolysin's IM injections. Together they provide broad-spectrum neurotrophic stimulation through different receptor pathways.

Compound	Dose	Route	Purpose
Cerebrolysin	5–10 mL daily	IM	Multi-component neurotrophic foundation; neuroplasticity, neuroregeneration
Semax	200–600 mcg daily	Intranasal	BDNF upregulation; cognitive enhancement; complementary nootropic mechanism

Protocol note: Run Semax concurrently during the Cerebrolysin cycle (10–20 days). Semax can also be continued during the inter-cycle rest period to maintain nootropic support while Cerebrolysin's neurotrophic cascades are still active. Semax cycles are typically 10–30 days.

Cerebrolysin + Selank — Neuroprotection + Anxiolysis

Selank is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin with demonstrated anxiolytic and nootropic properties. It modulates GABA-ergic neurotransmission and has neuroprotective effects. When combined with Cerebrolysin, it provides anxiolytic benefits alongside neurotrophic support — particularly useful for users experiencing stress-related cognitive impairment or anxiety.

Compound	Dose	Route	Purpose
Cerebrolysin	5–10 mL daily	IM	Neurotrophic foundation; neuroplasticity and neuroregeneration
Selank	250–500 mcg daily	Intranasal	Anxiolysis; GABA modulation; neuroprotection; stress-related cognitive support

Cerebrolysin + BPC-157 — Systemic Neuroprotection

BPC-157 is a gastric pentadecapeptide with demonstrated neuroprotective, cytoprotective, and tissue-healing properties. It acts on the gut–brain axis and has shown neuroprotective effects in animal models of brain injury. When combined with Cerebrolysin, the two peptides provide complementary neuroprotective mechanisms — Cerebrolysin through direct neurotrophic factor-like activity, and BPC-157 through nitric oxide system modulation, growth factor signaling, and gut–brain axis support.

Compound	Dose	Route	Purpose
Cerebrolysin	5–10 mL daily	IM	Direct neurotrophic support; neuroplasticity and neuroregeneration
BPC-157	250–500 mcg daily	SubQ or oral	Systemic neuroprotection; gut–brain axis; NO system modulation

Cerebrolysin + Semax + Selank — Triple Nootropic Stack

The most comprehensive nootropic peptide stack, engaging three distinct neurotrophic and neuromodulatory pathways simultaneously. Cerebrolysin provides the multi-component neurotrophic foundation, Semax upregulates BDNF through melanocortin pathways, and Selank adds anxiolytic GABA modulation and immunomodulatory neuroprotection. This is an advanced stack for experienced users.

Compound	Dose	Route	Purpose
Cerebrolysin	5–10 mL daily	IM	Multi-component neurotrophic foundation
Semax	200–600 mcg daily	Intranasal	BDNF upregulation; cognitive enhancement
Selank	250–500 mcg daily	Intranasal	Anxiolysis; GABA modulation; immunomodulatory neuroprotection

Start with individual compounds before stacking. Always establish your individual response to Cerebrolysin alone before adding complementary peptides. This allows you to identify which effects are attributable to which compound and to detect any adverse reactions. Add one additional peptide at a time, separated by at least one full Cerebrolysin cycle.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: Cerebrolysin has an extensive safety record based on over 40 years of clinical use in dozens of countries, thousands of patients in controlled clinical trials, and comprehensive post-marketing surveillance. It is generally well-tolerated at recommended doses when administered by the correct route (IM or IV). However, IV administration at higher doses requires clinical supervision, and specific contraindications must be observed.

Common Side Effects

Reported in clinical trials and post-marketing surveillance:

Headache — the most commonly reported side effect; usually mild and transient
Dizziness — more common with IV administration; usually resolves within hours
Injection site pain and soreness — with IM administration; rotating injection sites helps minimize this
Insomnia or agitation — particularly at higher doses (above 10 mL) or with evening administration; dose in the morning if sleep is affected
Feeling of warmth or flushing — during or shortly after IV infusion; generally harmless and self-limiting

Less common:

Nausea — more common with higher IV doses; may be reduced by slowing infusion rate
Fatigue or somnolence — paradoxical in some individuals despite agitation being more typical
Fever — rare; monitor and discontinue if persistent
Allergic reactions — rare; risk is higher in individuals with known allergy to porcine proteins
Vertigo — less common than dizziness; more associated with higher IV doses

Clinical trial safety data: In the CASTA stroke trial (n=1,070), the overall adverse event rate was similar between Cerebrolysin and placebo groups. Serious adverse events attributable to Cerebrolysin were rare. Meta-analyses of multiple trials confirm a favorable safety profile at standard therapeutic doses.

Contraindications

Epilepsy or seizure disorders — Cerebrolysin's neuroexcitatory properties can lower the seizure threshold. This is a well-established contraindication in the approved prescribing information. Do not use if you have a history of seizures without explicit medical clearance.
Severe renal impairment — impaired clearance of the amino acid and peptide load may lead to accumulation. Renal function should be assessed before initiating treatment.
Allergic diathesis — individuals with a predisposition to allergic reactions, particularly to porcine-derived products, should not use Cerebrolysin. Known hypersensitivity to any component is an absolute contraindication.
Pregnancy and breastfeeding — no adequate safety data exists for use during pregnancy or lactation. Avoid entirely.
Status epilepticus — active or recent status epilepticus is an absolute contraindication due to seizure threshold effects.

Drug Interactions

Antidepressants (MAOIs, SSRIs): Use with caution. Cerebrolysin may influence monoaminergic neurotransmission. Consult a physician if taking antidepressant medications.
Anticonvulsants: Cerebrolysin should not be combined with drugs that lower the seizure threshold. If taking anticonvulsants, medical supervision is essential.
Do not mix in the same syringe: Cerebrolysin should not be mixed with other drugs in the same syringe or infusion solution unless compatibility has been specifically established.

When to Stop or Reduce Dose

Persistent headache that does not resolve within the first 2–3 days of treatment
Significant insomnia or agitation that disrupts daily functioning — try reducing the dose first, then consider stopping if symptoms persist
Any signs of allergic reaction (skin rash, urticaria, swelling, difficulty breathing) — stop immediately and seek medical attention
Fever above 38°C (100.4°F) during treatment — discontinue and evaluate
Any seizure activity or unusual neurological symptoms — stop immediately and seek medical attention

Regulatory Status: Cerebrolysin is approved as a prescription drug in over 40 countries including Austria, Germany, Russia, China, South Korea, Mexico, and many others for stroke, TBI, and dementia. It is NOT approved by the FDA (US) or MHRA (UK). In the US, it is available only as a research compound. Regulations vary by jurisdiction — verify your local laws and prescription requirements before purchasing.

Common Cerebrolysin Dosing Mistakes

Avoid these common errors to get the most out of your Cerebrolysin protocol:

Injecting subcutaneously instead of intramuscularly or intravenously: Cerebrolysin is NOT a subcutaneous peptide. It must be administered IM or IV only. This is the most critical distinction from other peptides in this space. Subcutaneous injection is not a validated route and may result in poor absorption, local reactions, and unpredictable pharmacokinetics. Always use the IM route (for doses up to 5 mL) or IV route (for larger doses).

Using continuous daily dosing instead of short intensive cycles: Cerebrolysin is designed for short intensive cycles of 10–21 days, repeated every 3–6 months. This is based on decades of clinical protocol design. Continuous daily use for months has not been studied, is not recommended, and does not follow clinical practice. The neurotrophic effects persist well beyond the active treatment period due to downstream signaling cascades.

Attempting IV administration without clinical supervision: IV doses of Cerebrolysin, particularly above 10 mL, must be diluted in physiological saline and administered as a slow infusion under medical supervision. Self-administering IV infusions carries risks of air embolism, infection, phlebitis, and adverse reactions that require immediate medical response. IV administration is a clinical procedure — not a home protocol.

Exceeding 5 mL per IM injection site: A single intramuscular injection site (gluteal or deltoid) should not receive more than 5 mL of volume. Larger volumes cause excessive tissue distension, pain, and poor absorption. If your protocol calls for more than 5 mL, either split the dose across two IM sites or use the IV route. Most nootropic and moderate neurological protocols use 5–10 mL, making this a practical consideration.

Mixing Cerebrolysin with other drugs in the same syringe: Cerebrolysin should not be mixed with other medications in the same syringe or infusion bag unless specifically indicated. The complex peptide mixture may interact with other compounds, causing degradation, precipitation, or altered pharmacokinetics. Administer Cerebrolysin separately from other injectable medications.

Using Cerebrolysin if the solution is cloudy or discolored: Cerebrolysin should be a clear, amber-yellow solution. If the liquid appears cloudy, contains visible particles, or is discolored beyond its normal amber hue, do not use it. Compromised solutions may indicate protein aggregation, contamination, or degradation. Each ampule is single-use — discard any unused portion after opening.

Expecting immediate dramatic results from a single cycle: While some users report cognitive improvements within days, Cerebrolysin’s neurotrophic effects are cumulative and build over the course of a treatment cycle and beyond. Maximum benefits are often reported 2–4 weeks after completing a cycle as downstream neurotrophic cascades reach peak activation. Multiple cycles over time may produce greater cumulative benefit than any single cycle.

Ignoring contraindications, especially epilepsy: Cerebrolysin is contraindicated in patients with epilepsy or seizure disorders, severe renal impairment, and allergic diathesis. The neurotrophic and neuroexcitatory properties of the peptide mixture can lower the seizure threshold. This contraindication is well-established in the prescribing information across all countries where Cerebrolysin is approved. Do not use if you have a seizure history without explicit medical guidance.

Frequently Asked Questions

Key Takeaways

Cerebrolysin is a porcine brain-derived neuropeptide preparation — one of the most clinically studied neurotrophic compounds available, approved as a prescription drug in over 40 countries
IM or IV injection only — NEVER subcutaneous — this is the most critical administration rule and the biggest departure from typical research peptide protocols
Standard nootropic dose: 5 mL IM daily for 10–20 days — higher doses (10–50 mL IV) are used for neurological conditions under medical supervision
Short intensive cycles, not continuous use: 10–21 day treatment cycles repeated every 3–6 months; neurotrophic effects persist well beyond the active treatment period
Multi-modal neurotrophic mechanism — mimics BDNF, GDNF, CNTF, and NGF-like activity; promotes neuroplasticity, reduces neuroinflammation, supports neurogenesis
Best nootropic stack: Cerebrolysin + Semax for complementary neurotrophic support through different receptor pathways
Contraindicated in epilepsy — the neuroexcitatory properties can lower the seizure threshold. Also contraindicated in severe renal impairment and allergic diathesis
Generally well-tolerated — headache, dizziness, injection site pain, and insomnia are the most common side effects; serious adverse events are rare in clinical trial data
Ready-to-use solution — supplied in glass ampules at 215.2 mg/mL; no reconstitution needed. Single-use ampules only.
Not FDA-approved — available as a research compound in the US. Prescription drug in 40+ countries. Check local regulations before purchasing.

This article is for educational and informational purposes only. See our Disclaimer.

References

Heiss WD, et al. “Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA).” Stroke. 2012;43(3):630-636. PubMed
Muresanu DF, et al. “Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial.” Ann Neurol. 2016;80(5):677-685. PubMed
Alvarez XA, et al. “Cerebrolysin in Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled study with a 28-week treatment period.” Eur J Neurol. 2006;13(1):43-54. PubMed
Chen CC, et al. “Cerebrolysin for vascular dementia.” Cochrane Database Syst Rev. 2013;(1):CD008900. PubMed
Bornstein NM, et al. “Accelerated recovery from acute brain injuries: clinical efficacy of neurotrophic treatment in stroke and traumatic brain injury.” Drugs Today (Barc). 2012;48 Suppl A:43-61. PubMed
Muresanu DF, et al. “Efficacy and safety of Cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.” Neurol Sci. 2020;41(5):1171-1181. PubMed
Masliah E, et al. “Effects of Cerebrolysin on amyloid-beta deposition and synaptic pathology in APP transgenic mice.” J Neural Transm Suppl. 2002;(62):327-336. PubMed
Zhang Y, et al. “Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury.” J Neurosurg. 2015;122(4):843-855. PubMed
Alvarez XA, et al. “A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.” Eur J Neurol. 2011;18(1):59-68.
Ziganshina LE, et al. “Cerebrolysin for acute ischaemic stroke.” Cochrane Database Syst Rev. 2017;(4):CD007026.
Plosker GL, Gauthier S. “Cerebrolysin: a review of its use in dementia.” Drugs Aging. 2009;26(11):893-915.

Next Steps

Continue your research with these resources.

BPC-157 Dosage Guide

Learn dosing protocols for BPC-157 — a versatile neuroprotective and tissue-healing peptide that complements Cerebrolysin’s neurotrophic effects.

Read Guide

Dosage Calculator

Plan your Cerebrolysin protocol with precise volume and supply calculations.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory